Table 4.
An aspirational vaccination programme for Asian practitioners
| Type of vaccine | Puppy or kitten vaccination | Adult animal revaccination |
|---|---|---|
|
Quality‐assured core MLV vaccines For dogs including CDV, CAV‐2 and CPV‐2 For cats including FPV, FCV and FHV‐1 |
Start at 8 to 9 weeks of age with first vaccine; give a second vaccine 3 to 4 weeks later with a third vaccine to be given at 16 weeks of age or older A booster vaccine should be given 12 months later or at 12 months of age |
Revaccination with core, quality‐assured MLV vaccines should be no more frequent than every 3 years. Serology might be used to monitor protective immunity (for CDV, CAV, CPV and FPV) and aid decision making on revaccination intervals The single exception to this may be cats at high risk of contacting upper respiratory virus, in which these components may be given annually |
| Quality‐assured canine rabies vaccine for dogs or cats | According to datasheet recommendations; one dose from 12 weeks of age. The VGG recommends that in high‐risk areas a second dose may be given 4 weeks later | Quality‐assured canine rabies vaccines all carry a 3‐year licensed DOI in most countries outside of Asia |
|
Non‐core vaccines Examples for dogs: Leptospira, canine infectious respiratory disease complex (kennel cough) Examples for cats: feline leukaemia virus, Bordetella or Chlamydophila |
Give according to the manufacturer's recommendations: generally two doses 2 to 4 weeks apart | Non‐core vaccines are generally given annually unless the datasheet specifically recommends otherwise (e.g. some quality‐assured FeLV vaccines carry a longer DOI) |
|
Not recommended vaccines These include vaccines against coronavirus (canine or feline), feline immunodeficiency virus and Giardia |
The generic information in this table should be read in conjunction with the more detailed recommendations provided in the current WSAVA vaccination guidelines (Day et al. 2010). Vaccination according to WSAVA guidelines is possible only where available product ranges separate core from non‐core vaccine components. Note that these recommendations apply only to quality‐assured vaccines, most of which are produced by large, international companies